Company Announcements

N-of-One signed a business partner agreement with Affymetrix in May to provide CNV analysis interpretation for Affymetrix OncoScan assay customers.

KromaTiD announced a distribution agreement with Tokyo Future Style for Japan.

Sigma-Aldrich entered into an agreement with XCell Science to launch genetically engineered human neural-differentiated cells and accompanying culture media for neurological disease research.

In June, synthetic DNA firm Twist Bioscience completed a $37 million Series C financing, led by Illumina. Nicholas J. Naclerio, PhD, Illumina’s senior vice president of Corporate Development and general manager of Enterprise Informatics, joined the Board.

Horizon Discovery and DefiniGEN are collaborating to develop a range of unique gene-engineered iPS-based cell lines for research. The cell line reagents will be available through DefiniGEN and comarketed by Horizon.

Synthetic Genomics licensed its Febit IP estate (see IBO 9/30/12) to Gen9. The technology includes methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA.

Reagency announced a distribution and marketing agreement with Stratech Scientific for the UK and Ireland.

Product Introductions

In May, InDevR launched the new and rebranded VaxArray Influenza potency assay, a multiplexed immunoassay for hemagglutinin quantification.

Exiqon released the new Antisense LNA GapmeRs for targeted inactivation of RNA in functional studies.

In June, Bio-Rad Laboratories introduced the first set in a new product line of PrecisionAb Antibodies rigorously validated for use in western blotting.

Agilent Technologies released updates to its SurePrint gene expression microarrays for mRNA profiling applications for human, mouse and rat models, including IncRNA expression.

Oxford Gene Technology introduced the Cytosure Constitutional v3 arrays for studying developmental disorders.

In June, Abcam launched the Multiplex Cellular miRNA Assay and Multiplex Circulating miRNA Assay for high-throughput validation of miRNA biomarkers. They profile up to 68 miRNAs in each well of a 96-well plate with a readout using a standard flow cytometer.

For use in downstream experiments, Lonza released the L7 PBMC (peripheral blood mononuclear cells) Reprogramming Bundle for its L7 workflow for reprogramming.

Bioo Scientific introduced the MaxSignal TMB Microwell Substrate Solution, a one-component tetramethylbenzidine formulation with a three-year shelf life. It contains no DMF or DMSO and is noncarcinogenic.